Are anti-HER2 agents the best choice in metastatic breast cancer with an HER2 positive switch from primary tumour? A retrospective multi institution analysis of clinical-pathological characteristics and outcomes
Titel:
Are anti-HER2 agents the best choice in metastatic breast cancer with an HER2 positive switch from primary tumour? A retrospective multi institution analysis of clinical-pathological characteristics and outcomes
Auteur:
Bertolini, I. Diodati, L. Fontana, A. De Angelis, C. Cantini, L. Cecconi, S. Montagnani, I. Salvadori, B. Ferrarini, I. Ferrari, P. Michelotti, A. Landucci, E. Fanelli, G. Scatena, C. Naccarato, A.G. Berardi, R. Pistelli, M. Falcone, A.